Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off FDA IND Filing Process with Granted CRO Contract to California-Based InClin, Inc.
Lexaria just awarded InClin, Inc. the contract for CRO services, in a move that lines up with the company’s upcoming FDA-registered, U.S. Phase 1b IND hypertension study, HYPER-H23-1 InClin will manage the study in the form of clinical site evaluation and selection, project management, personnel, site training, and more Patient dosing is set to kick off as soon as possible once the expected FDA IND filing and review is completed, which Lexaria hopes will be done this summer HYPER-H23-1 will be Lexaria’s most ambitious study yet, and upon its completion, it will move the company closer to FDA approval of…